Blood Cell Profiles as Predictors of Treatment Response and Outcomes in Neoadjuvant Immunotherapy with Chemotherapy for Esophageal Squamous Cell Carcinoma - Scorecard - MDSpire
Advertisement
Blood Cell Profiles as Predictors of Treatment Response and Outcomes in Neoadjuvant Immunotherapy with Chemotherapy for Esophageal Squamous Cell Carcinoma
Clinical Scorecard: Blood Cell Profiles as Predictors of Treatment Response and Outcomes in Neoadjuvant Immunotherapy with Chemotherapy for Esophageal Squamous Cell Carcinoma
At a Glance
Category
Detail
Condition
Esophageal Squamous Cell Carcinoma (ESCC)
Key Mechanisms
Neoadjuvant immunotherapy combined with chemotherapy
Target Population
Patients with locally advanced ESCC (clinical stage II–IVA)
Care Setting
Multidisciplinary treatment including surgery
Key Highlights
Neoadjuvant therapy is the standard treatment for locally advanced ESCC.
Immunotherapy combined with chemotherapy is recommended for unresectable cases.
Blood cell profiles may predict treatment efficacy and prognosis.
Postoperative complications include lung infection and anastomotic leakage.
Pathological complete response (PCR) is the primary therapeutic response measure.
Guideline-Based Recommendations
Diagnosis
Use AJCC/UICC TNM classification for staging.
Management
Administer two cycles of neoadjuvant immunotherapy (sintilimab) combined with chemotherapy.
Monitoring & Follow-up
Follow-up with CT imaging and clinical assessments post-treatment.
Risks
Monitor for major complications such as lung infection and anastomotic leakage.
Patient & Prescribing Data
91 patients aged 48–80 years with clinical stage II–IVA ESCC
Patients received nedaplatin and docetaxel/nabpaclitaxel with sintilimab.
Clinical Best Practices
Ensure complete clinicopathological data for patient selection.
Reassess surgical feasibility after neoadjuvant treatment.
Utilize CAP criteria for grading tumor regression.
